D. P. Petrylak Et Al. , "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial," LANCET ONCOLOGY , vol.21, no.1, pp.105-120, 2020
Petrylak, D. P. Et Al. 2020. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY , vol.21, no.1 , 105-120.
Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., ... Castellano, D.(2020). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY , vol.21, no.1, 105-120.
Petrylak, Daniel Et Al. "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial," LANCET ONCOLOGY , vol.21, no.1, 105-120, 2020
Petrylak, Daniel P. Et Al. "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial." LANCET ONCOLOGY , vol.21, no.1, pp.105-120, 2020
Petrylak, D. P. Et Al. (2020) . "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial." LANCET ONCOLOGY , vol.21, no.1, pp.105-120.
@article{article, author={Daniel P. Petrylak Et Al. }, title={Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2020, pages={105-120} }